• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Xbiotech Inc (NQ: XBIT )

    7.460 +0.160 (+2.19%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 24,447
    Open 7.250
    Bid (Size) 7.380 (2)
    Ask (Size) 7.460 (2)
    Prev. Close 7.300
    Today's Range 7.250 - 7.510
    52wk Range 3.510 - 9.960
    Shares Outstanding 30,436,964
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    XBIT Stock Earnings: XBiotech Reported Results for Q2 2024
    XBiotech just reported results for the second quarter of 2024. 
    Via InvestorPlace
    What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
    XBiotech reveals results from its Phase 1/Phase 2 1-BETTER Study for advanced pancreatic cancer, highlighting the safety and tolerability of Natrunix with the ONIVYDE + 5-Fluorouracil + Leucovorin... 
    Via Benzinga

    Performance

    YTD
    +71.89%
    +71.89%
    1 Month
    +3.76%
    +3.76%
    3 Month
    +20.13%
    +20.13%
    6 Month
    -20.47%
    -20.47%
    1 Year
    +79.76%
    +79.76%

    More News

    Read More
    XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
    From XBiotech Inc.
    Via GlobeNewswire
    XBIT Stock Earnings: XBiotech Reported Results for Q1 2024
    Via InvestorPlace
    XBIT Stock Earnings: XBiotech Reported Results for Q4 2023
    Via InvestorPlace
    Stocks That Hit 52-Week Lows On Thursday
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
    From XBiotech Inc.
    Via GlobeNewswire
    Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
    From XBiotech Inc.
    Via GlobeNewswire
    XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
    From XBiotech Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
    From XBiotech Inc.
    Via GlobeNewswire
    XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
    From XBiotech Inc.
    Via GlobeNewswire
    FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
    From XBiotech Inc.
    Via GlobeNewswire
    Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Dow Jumps Over 100 Points; US Housing Starts Rise In April
    Via Benzinga
    XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
    From XBiotech Inc.
    Via GlobeNewswire
    XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
    From XBiotech Inc.
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
    From XBiotech Inc.
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    Stocks That Hit 52-Week Lows On Wednesday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.